278
side effects limiting the possible therapeutic response [1, 2]. Nanoparticle (NP)
based approaches offer a valuable alternative for cancer drug delivery, functioning
as a carrier for entry through fenestrations in tumor vasculature, thus allowing direct
cell access and ensuring the accumulation of high concentrations of drug to the
targeted cancer cell, with a concomitant reduced toxicity of healthy tissue. In this
contest, superparamagnetic iron oxide NPs (SPIONs) are very attractive for delivery
of therapeutic agents as enhance the drug delivery to specific locations in the body
through the application of an external magnetic field [3, 4]. To make more biocompatible and protect the drug, solid lipid NPs (SLN) has been used to contain sorafenib
and SPIONs by means of hot homogenization technique using cetyl palmitate as
lipid matrix and polyethylene glycol modified phospholipids (PEG lipids), in order
to achieve a PEG-based anti-fouling coating on SLN surface. These nanoformulations, thoroughly investigated by means of complementary techniques, have finally
resulted effective drug delivery magnetic nanovectors with good stability in aqueous medium and high drug encapsulation efficiency (>90%). In addition, the magnetic relaxometric characterization has proven that the SLN loaded with sorafenib
and SPION are also very efficient contrast agents, with a great potential in magnetic
resonance imaging (MRI) technique. Cellular uptake on HepG2 cell line shows a
better effectiveness of antitumoral action of sorafenib when it is encapsulated in
SLN and subjected to magnetic field. The proposed magnetic SLNs loaded with
sorafenib represent promising candidates for image guided and magnetic targeting
of sorafenib to liver towards an efficacious treatment of HCC.
References
1. Villanueva A et al. (2011) Gastroenterology 140:1410–1426
2. El-Serag HB et al. (2008) Gastroenterology 134:1752–1763
3. Depalo N et al. (2017) Nanoresearch 5:1909–1917
4. Hervault A et al. (2014) Nanoscale 6:11553–11573
F. Vischio et al.
side effects limiting the possible therapeutic response [1, 2]. Nanoparticle (NP)
based approaches offer a valuable alternative for cancer drug delivery, functioning
as a carrier for entry through fenestrations in tumor vasculature, thus allowing direct
cell access and ensuring the accumulation of high concentrations of drug to the
targeted cancer cell, with a concomitant reduced toxicity of healthy tissue. In this
contest, superparamagnetic iron oxide NPs (SPIONs) are very attractive for delivery
of therapeutic agents as enhance the drug delivery to specific locations in the body
through the application of an external magnetic field [3, 4]. To make more biocompatible and protect the drug, solid lipid NPs (SLN) has been used to contain sorafenib
and SPIONs by means of hot homogenization technique using cetyl palmitate as
lipid matrix and polyethylene glycol modified phospholipids (PEG lipids), in order
to achieve a PEG-based anti-fouling coating on SLN surface. These nanoformulations, thoroughly investigated by means of complementary techniques, have finally
resulted effective drug delivery magnetic nanovectors with good stability in aqueous medium and high drug encapsulation efficiency (>90%). In addition, the magnetic relaxometric characterization has proven that the SLN loaded with sorafenib
and SPION are also very efficient contrast agents, with a great potential in magnetic
resonance imaging (MRI) technique. Cellular uptake on HepG2 cell line shows a
better effectiveness of antitumoral action of sorafenib when it is encapsulated in
SLN and subjected to magnetic field. The proposed magnetic SLNs loaded with
sorafenib represent promising candidates for image guided and magnetic targeting
of sorafenib to liver towards an efficacious treatment of HCC.
References
1. Villanueva A et al. (2011) Gastroenterology 140:1410–1426
2. El-Serag HB et al. (2008) Gastroenterology 134:1752–1763
3. Depalo N et al. (2017) Nanoresearch 5:1909–1917
4. Hervault A et al. (2014) Nanoscale 6:11553–11573
F. Vischio et al.